Olaparib made available on the NHS for BRCA-positive ovarian cancer patients

Photo credit: NIH NCI Visuals Online AstraZeneca and MSD (both UK) today announced that Lynparza® (olaparib) is now recommended for use within the Cancer Drugs Fund via the NHS in England  as a treatment option for the BRCA mutation-positive, advanced high-grade epithelial ovarian, fallopian tube or primary peritneal cancer that has responded to first-line platinum-based chemotherapy in adults.Ovarian cancer is one of the most common types of cancer affecting women in the UK. Approximately, 60% of patients are diagnosed at an advanced stage, when chances of survival are significantly reduced, and of those who are cleared, 70% will relapse within...